204 related articles for article (PubMed ID: 14767540)
1. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
Tsuchida T; Kijima H; Hori S; Oshika Y; Tokunaga T; Kawai K; Yamazaki H; Ueyama Y; Scanlon KJ; Tamaoki N; Nakamura M
Cancer Gene Ther; 2000 Mar; 7(3):373-83. PubMed ID: 10766343
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
4. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
[TBL] [Abstract][Full Text] [Related]
5. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
[TBL] [Abstract][Full Text] [Related]
6. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
[TBL] [Abstract][Full Text] [Related]
7. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line.
Tokunaga T; Tsuchida T; Kijima H; Okamoto K; Oshika Y; Sawa N; Ohnishi Y; Yamazaki H; Miura S; Ueyama Y; Nakamura M
Br J Cancer; 2000 Sep; 83(6):833-9. PubMed ID: 10952790
[TBL] [Abstract][Full Text] [Related]
8. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity.
Aoki K; Yoshida T; Sugimura T; Terada M
Cancer Res; 1995 Sep; 55(17):3810-6. PubMed ID: 7641198
[TBL] [Abstract][Full Text] [Related]
9. Molecular target-based therapy of pancreatic cancer.
Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
[TBL] [Abstract][Full Text] [Related]
10. Stability of ras oncogene mutation in the human tumor xenografts through serial passages.
Kijima H; Abe Y; Yamazaki H; Ohnishi Y; Ueyama Y; Tamaoki N; Nakamura M
Anticancer Res; 1994; 14(6B):2583-7. PubMed ID: 7872685
[TBL] [Abstract][Full Text] [Related]
11. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
[TBL] [Abstract][Full Text] [Related]
12. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice.
Reyes G; Villanueva A; García C; Sancho FJ; Piulats J; Lluís F; Capellá G
Cancer Res; 1996 Dec; 56(24):5713-9. PubMed ID: 8971180
[TBL] [Abstract][Full Text] [Related]
13. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T
Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909
[TBL] [Abstract][Full Text] [Related]
14. [Point mutation at codon 12 of c-Ki-ras oncogene in human pancreatic neoplasms and normal human pancreas tissue].
Cui Q; Wang Z; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Jun; 16(3):201-5. PubMed ID: 7805165
[TBL] [Abstract][Full Text] [Related]
15. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
Miura Y; Ohnami S; Yoshida K; Ohashi M; Nakano M; Ohnami S; Fukuhara M; Yanagi K; Matsushita A; Uchida E; Asaka M; Yoshida T; Aoki K
Cancer Lett; 2005 Jan; 218(1):53-62. PubMed ID: 15639340
[TBL] [Abstract][Full Text] [Related]
17. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
Takeuchi M; Shichinohe T; Senmaru N; Miyamoto M; Fujita H; Takimoto M; Kondo S; Katoh H; Kuzumaki N
Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026
[TBL] [Abstract][Full Text] [Related]
18. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
20. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
Eastham JA; Ahlering TE
J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
